Your browser doesn't support javascript.
loading
ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker, Michael; Wagner, Juliane; Kreyenberg, Hermann; Heim, Catrin; Moser, Laura M; Wels, Winfried S; Bonig, Halvard; Ivics, Zoltán; Ullrich, Evelyn; Klingebiel, Thomas; Bader, Peter; Rettinger, Eva.
Afiliação
  • Merker M; Division for Stem Cell Transplantation, Immunology, and Intensive Care Medicine, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
  • Wagner J; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.
  • Kreyenberg H; Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany.
  • Heim C; Division of Medical Biotechnology, Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
  • Moser LM; Division for Stem Cell Transplantation, Immunology, and Intensive Care Medicine, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
  • Wels WS; Division for Stem Cell Transplantation, Immunology, and Intensive Care Medicine, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
  • Bonig H; Division for Stem Cell Transplantation, Immunology, and Intensive Care Medicine, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
  • Ivics Z; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.
  • Ullrich E; Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany.
  • Klingebiel T; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
  • Bader P; Department of Cellular Therapeutics/Cell Processing (Good Manufacturing Practice, GMP), Institute for Transfusion Medicine and Immunotherapy, Goethe University, Frankfurt, Germany.
  • Rettinger E; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, United States.
Front Immunol ; 11: 581468, 2020.
Article em En | MEDLINE | ID: mdl-33193388
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Células Matadoras Naturais / Receptor ErbB-2 / Células Matadoras Induzidas por Citocinas / Receptores de Antígenos Quiméricos / Imunidade Inata Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adolescent / Animals / Humans / Male Idioma: En Revista: Front Immunol Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Células Matadoras Naturais / Receptor ErbB-2 / Células Matadoras Induzidas por Citocinas / Receptores de Antígenos Quiméricos / Imunidade Inata Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adolescent / Animals / Humans / Male Idioma: En Revista: Front Immunol Ano de publicação: 2020 Tipo de documento: Article